We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

58 hedge funds and large institutions have $9.31M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,700% more call options, than puts

Call options by funds: $28K | Put options by funds: $1K

6% more capital invested

Capital invested by funds: $8.79M → $9.31M (+$520K)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

5% less funds holding

Funds holding: 61 → 58 (-3)

10% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 10

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
12
Reduced
13
Closed
10
Calls
$28K
Puts
$1K
Net Calls
+$27K
Net Calls Change
-$38K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$572K
2
KCM
Kennedy Capital Management
Missouri
+$267K
3
TSS
Two Sigma Securities
New York
+$54.1K
4
BC
BIT Capital
Germany
+$48.3K
5
WCA
Waypoint Capital Advisors
Minnesota
+$38.1K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$735K
2
Two Sigma Investments
Two Sigma Investments
New York
-$180K
3
E
Ergoteles
New York
-$87.8K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$79.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
VFA
26
Valeo Financial Advisors
Indiana
$34.5K – – –
Charles Schwab
27
Charles Schwab
California
$32.2K – – –
BWG
28
Beta Wealth Group
California
$32K – – –
AAM
29
Aureus Asset Management
Massachusetts
$30.2K – – –
OQS
30
Occudo Quantitative Strategies
Florida
$25.6K -$1.49K -75 -6%
IIA
31
IPG Investment Advisors
California
$23.7K – – –
SPC
32
Sigma Planning Corp
Michigan
$20K – – –
Mackenzie Financial
33
Mackenzie Financial
Ontario, Canada
$19.9K – – –
Osaic Holdings
34
Osaic Holdings
Arizona
$19K -$975 -49 -5%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$17.6K – – –
BWP
36
Balboa Wealth Partners
Arizona
$17.5K – – –
SSA
37
Schonfeld Strategic Advisors
New York
$12.8K -$7.46K -375 -37%
E
38
Ergoteles
New York
$12.4K -$87.8K -4,409 -88%
HCM
39
Hollencrest Capital Management
California
$11K +$10.9K +550 New
MFG
40
Merit Financial Group
Georgia
$10K – – –
VWA
41
Visionary Wealth Advisors
Illinois
$10K – – –
Bank of America
42
Bank of America
North Carolina
$7.06K +$60 +3 +0.9%
Simplex Trading
43
Simplex Trading
Illinois
$7K +$2.27K +114 +43%
Wells Fargo
44
Wells Fargo
California
$6.34K +$20 +1 +0.3%
Citadel Advisors
45
Citadel Advisors
Florida
$5.51K +$5.49K +276 New
NSIM
46
North Star Investment Management
Illinois
$5K – – –
UBS Group
47
UBS Group
Switzerland
$4.76K -$11.8K -594 -71%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$4.46K – – –
CCA
49
Column Capital Advisors
Indiana
$1.45K +$1.45K +73 New
Fidelity Investments
50
Fidelity Investments
Massachusetts
$1.43K -$995 -50 -41%
1
2
3

ONCT Hedge Fund Activity: Q4 2022 in Review

58 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2022, worth a combined $9.31M — up 5.9% from $8.79M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of ONCT and 9 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.

The largest buyer was Millennium Management, adding an estimated $572K. The largest seller was Renaissance Technologies, cutting an estimated $735K.

  • 58 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2022, down from 61 in Q3 2022.
  • Funds reported $9.31M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2022, up 5.9% quarter-over-quarter.
  • 9 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -1 holder.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2022 was Millennium Management, an estimated $572K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2022 was Renaissance Technologies, an estimated $735K sold.

Based on aggregated 13F filings for Q4 2022.